Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

SBTX

Silverback Therapeutics (SBTX)

Silverback Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SBTX
일자시간출처헤드라인심볼기업
2023/06/2905:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/1522:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/1522:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/0922:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/0905:35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/0205:42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SBTXSilverback Therapeutics Inc
2023/05/0205:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SBTXSilverback Therapeutics Inc
2023/03/2405:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/03/2405:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/03/1322:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/02/2406:01GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsNASDAQ:SBTXSilverback Therapeutics Inc
2023/02/2306:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2023/02/2306:05GlobeNewswire Inc.ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
2023/02/1406:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SBTXSilverback Therapeutics Inc
2023/02/0920:30GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/1807:07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/1806:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2023/01/0607:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2022/12/1007:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2022/12/0707:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
2022/12/0206:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
2022/12/0106:24Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SBTXSilverback Therapeutics Inc
2022/11/2206:08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
2022/11/1907:07Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
 검색 관련기사 보기:NASDAQ:SBTX